CLINICAL_TRIALS ClinicalTrials.gov record update

Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02066662
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:58.579014+00:00
Published At: 2020-10-22T00:00:00+00:00
Record Updated At: 2020-10-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Atrial Fibrillation or Pulmonary Embolism", "Need of Long Term Oral Anticoagulation Therapy (OAT)", "Existent Coronary or Valvular Calcification, or Both and Agatston Score \u003e 50 in at Least One Location"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-10-22"
protocolSection.identificationModule.nctId: "NCT02066662"
protocolSection.identificationModule.officialTitle: "Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.